Axicabtagene ciloleucel

Generic Name
Axicabtagene ciloleucel
Brand Names
Yescarta
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
U2I8T43Y7R
Background

Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and kill canc...

Indication

In the US, axicabtagene ciloleucel is indicated for the treatment of adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
...

Associated Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Follicular Lymphoma, Refractory Large B-cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Follicular Lymphoma, Refractory High Grade B-cell Lymphoma (HGBCL), Relapsed High Grade B-cell Lymphoma (HGBCL), Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Associated Therapies
-
Clinical Trials
Related News

Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Phase 4
Recruiting
Conditions
Lymphoma, B-Cell
Interventions
Biological: Axicabtagene Ciloleucel
First Posted Date
2024-09-24
Last Posted Date
2024-10-11
Lead Sponsor
Not specified
Target Recruit Count
20
Registration Number
NCT06609304
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Zhengzhou, Henan, China

Emapalumab Prevention of CAR-T Cell Associated Toxicities

First Posted Date
2024-08-12
Last Posted Date
2024-12-19
Lead Sponsor
Marcela V. Maus, M.D.,Ph.D.
Target Recruit Count
28
Registration Number
NCT06550141
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination with Radiotherapy (RT) in Relapsed/refractory Follicular Lymphoma

First Posted Date
2023-09-21
Last Posted Date
2024-11-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT06043323
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

First Posted Date
2023-04-03
Last Posted Date
2024-06-13
Lead Sponsor
Stanford University
Target Recruit Count
20
Registration Number
NCT05794958
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

First Posted Date
2023-03-20
Last Posted Date
2024-11-19
Lead Sponsor
Kite, A Gilead Company
Registration Number
NCT05776160
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

🇺🇸

Northside Hospital, Atlanta, Georgia, United States

and more 103 locations

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

First Posted Date
2022-12-01
Last Posted Date
2024-12-20
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
396
Registration Number
NCT05633615
Locations
🇺🇸

Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States

🇺🇸

Highlands Oncology Group - Rogers, Rogers, Arkansas, United States

🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

and more 73 locations

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

First Posted Date
2022-11-04
Last Posted Date
2024-12-06
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
300
Registration Number
NCT05605899
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

🇺🇸

University of California Los Angeles (UCLA), Los Angeles, California, United States

and more 84 locations

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

First Posted Date
2022-07-15
Last Posted Date
2024-10-04
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
30
Registration Number
NCT05459571
Locations
🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 13 locations

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

First Posted Date
2022-05-12
Last Posted Date
2024-11-22
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
230
Registration Number
NCT05371093
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States

🇺🇸

UC Irvine Health, Orange, California, United States

and more 65 locations

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

First Posted Date
2021-10-14
Last Posted Date
2024-11-08
Lead Sponsor
AIDS Malignancy Consortium
Target Recruit Count
20
Registration Number
NCT05077527
Locations
🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy